![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FJ Monsma , Y Shen, RP Ward, MW Hamblin and DR Sibley
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
We have used the polymerase chain reaction technique to selectively amplify a guanine nucleotide-binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned serotonin receptors. Sequencing of a full length clone isolated from a rat striatal cDNA library revealed an open reading frame of 1311 base pairs, encoding a 437-residue protein with seven hydrophobic regions. Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5- hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E. Northern blots revealed a approximately 4.2-kilobase transcript localized in various brain regions, with the following rank order of abundance: striatum >> olfactory tubercle > cerebral cortex > hippocampus. Expression of this clone in COS-7 cells resulted in the appearance of high affinity, saturable binding of (+)-[2-125I] iodolysergic acid diethylamide ([125I]LSD) with a Kd of 1.26 nM. Among endogenous biogenic amines, only 5-HT completely inhibited [125I]LSD binding (Ki = 150 nM). The inhibition of [125I]LSD binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described serotonin receptor subtype. In addition, this receptor exhibits high affinity for a number of tricyclic antipsychotic and antidepressant drugs, including clozapine, amoxipine, and amitriptyline. In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity, which is blocked by antipsychotic and antidepressant drugs. The distinct structural and pharmacological properties of this receptor site indicate that it represents a completely novel subtype of serotonin receptor. Based on its affinity for tricyclic psychotropic drugs and its localization to limbic and cortical regions of the brain, it is likely that this receptor may play a role in several neuropsychiatric disorders that involve serotonergic systems.
This article has been cited by other articles:
|
|
 |
|
  J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation J. Neurosci., April 11, 2007; 27(15): 4201 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Grider Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G319 - G327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Setola and B. L. Roth Why Mice Are Neither Miniature Humans nor Small Rats: A Cautionary Tale Involving 5-Hydroxytryptamine-6 Serotonin Receptor Species Variants Mol. Pharmacol., December 1, 2003; 64(6): 1277 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
W. D. Hirst, B. Abrahamsen, F. E. Blaney, A. R. Calver, L. Aloj, G. W. Price, and A. D. Medhurst Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular Modeling Mol. Pharmacol., December 1, 2003; 64(6): 1295 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Lindner, D. B. Hodges Jr., J. B. Hogan, A. F. Orie, J. A. Corsa, D. M. Barten, C. Polson, B. J. Robertson, V. L. Guss, K. W. Gillman, et al. An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 682 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-E. Andersson Pharmacology of Penile Erection Pharmacol. Rev., September 1, 2001; 53(3): 417 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cravchik and D. Goldman Neurochemical Individuality: Genetic Diversity Among Human Dopamine and Serotonin Receptors and Transporters Arch Gen Psychiatry, December 1, 2000; 57(12): 1105 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Morris and C. C. Malbon Physiological Regulation of G Protein-Linked Signaling Physiol Rev, October 1, 1999; 79(4): 1373 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Contesse, S. Lenglet, L. Grumolato, Y. Anouar, I. Lihrmann, H. Lefebvre, C. Delarue, and H. Vaudry Pharmacological and Molecular Characterization of 5-Hydroxytryptamine7 Receptors in the Rat Adrenal Gland Mol. Pharmacol., September 1, 1999; 56(3): 552 - 561. [Abstract] [Full Text]
|
|
|
|
|
|
G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. John, P. J. Pauwels, M. Perez, S. Halazy, B. Le Grand, Y. Verscheure, J.-P. Valentin, C. Palmier, T. Wurch, P. Chopin, et al. F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 83 - 95. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. E. Scrogin, A. K. Johnson, and H. A. Schmid Multiple receptor subtypes mediate the effects of serotonin on rat subfornical organ neurons Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1998; 275(6): R2035 - R2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, A. Gobert, A. Newman-Tancredi, V. Audinot, F. Lejeune, J.-M. Rivet, D. Cussac, J.-P. Nicolas, O. Muller, and G. Lavielle S 16924 ((R)-2-{1-[2-(2,3-Dihydro-Benzo[1,4] Dioxin-5-Yloxy)-Ethyl]-Pyrrolidin-3yl}-1-(4-Fluoro-Phenyl)-Ethanone), a Novel, Potential Antipsychotic with Marked Serotonin (5-HT)1A Agonist Properties: I. Receptorial and Neurochemical Profile in Comparison with Clozapine and Haloperidol J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1341 - 1355. [Abstract] [Full Text]
|
|
|
|
|
|
F. G. Boess, C. Riemer, M. Bös, J. Bentley, A. Bourson, and A. J. Sleight The 5-Hydroxytryptamine6 Receptor-Selective radioligand [3H]Ro 63-0563 Labels 5-Hydroxytryptamine Receptor Binding Sites in Rat and Porcine Striatum Mol. Pharmacol., September 1, 1998; 54(3): 577 - 583. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. P. Baker, M. D. Nielsen, S. Impey, M. A. Metcalf, S. W. Poser, G. Chan, K. Obrietan, M. W. Hamblin, and D. R. Storm Stimulation of Type 1 and Type 8 Ca2+/Calmodulin-sensitive Adenylyl Cyclases by the Gs-coupled 5-Hydroxytryptamine Subtype 5-HT7A Receptor J. Biol. Chem., July 10, 1998; 273(28): 17469 - 17476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. De Vry, R. Schohe-Loop, H.-G. Heine, J. M. Greuel, F. Mauler, B. Schmidt, H. Sommermeyer, and T. Glaser Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1082 - 1094. [Abstract] [Full Text]
|
|
|
|
|
|
F. G. Boess, F. J. Monsma Jr., V. Meyer, C. Zwingelstein, and A. J. Sleight Interaction of Tryptamine and Ergoline Compounds with Threonine 196 in the Ligand Binding Site of the 5-Hydroxytryptamine6 Receptor Mol. Pharmacol., September 1, 1997; 52(3): 515 - 523. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Delay, S. C. Kinnamon, and S. D. Roper Serotonin Modulates Voltage-Dependent Calcium Current in Necturus Taste Cells J Neurophysiol, May 1, 1997; 77(5): 2515 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barondes Thinking about Prozac Science, February 25, 1994; 263(5150): 1102 - 1103. [PDF]
|
|
|
|
 |
|
 C. Moret and M. Briley The unique effect of methiothepin on the terminal serotonin autoreceptor in the rat hypothalamus could be an example of inverse agonism J Psychopharmacol, January 1, 1993; 7(4): 331 - 337. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
